Comparative Action of Cardiotonic Steroids on Intracellular Processes in Rat Cortical Neurons


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Binding to Na+,K+-ATPase, cardiotonic steroids (CTS) activate intracellular signaling cascades that affect gene expression and regulation of proliferation and apoptosis in cells. Ouabain is the main CTS used for studying these processes. The effects of other CTS on nervous tissue are practically uncharacterized. Previously, we have shown that ouabain affects the activation of mitogen-activated protein kinases (MAP kinases) ERK1/2, p38, and JNK. In this study, we compared the effects of digoxin and bufalin, which belong to different subclasses of CTS, on primary culture of rat cortical cells. We found that CTS toxicity is not directly related to the degree of Na+,K+-ATPase inhibition, and that bufalin and digoxin, like ouabain, are capable of activating ERK1/2 and p38, but with different concentration and time profiles. Unlike bufalin and ouabain, digoxin did not decrease JNK activation after long-term incubation. We concluded that the toxic effect of CTS in concentrations that inhibit less than 80% of Na+,K+-ATPase activity is related to ERK1/2 activation as well as the complex profile of MAP kinase activation. A direct correlation between Na+,K+-ATPase inhibition and the degree of MAP kinase activation is only observed for ERK1/2. The different action of the three CTS on JNK and p38 activation may indicate that it is associated with intracellular signaling cascades triggered by protein–protein interactions between Na+,K+-ATPase and various partner proteins. Activation of MAP kinase pathways by these CTS occurs at concentrations that inhibit Na+,K+-ATPase containing the α1 subunit, suggesting that these signaling cascades are realized via α1. The results show that the signaling processes in neurons caused by CTS can differ not only because of different inhibitory constants for Na+,K+-ATPase.

About the authors

A. V. Lopachev

Research Center of Neurology

Email: akkuratov.evgeny@gmail.com
Russian Federation, Moscow, 125367

O. M. Lopacheva

Research Center of Neurology; International Biotechnological Center

Email: akkuratov.evgeny@gmail.com
Russian Federation, Moscow, 125367; Moscow, 119991

K. A. Nikiforova

Institute of General Pathology and Pathophysiology

Email: akkuratov.evgeny@gmail.com
Russian Federation, Moscow, 125315

I. S. Filimonov

International Biotechnological Center

Email: akkuratov.evgeny@gmail.com
Russian Federation, Moscow, 119991

T. N. Fedorova

Research Center of Neurology

Email: akkuratov.evgeny@gmail.com
Russian Federation, Moscow, 125367

E. E. Akkuratov

Science for Life Laboratory, Department of Applied Physics; Institute of Translational Biomedicine

Author for correspondence.
Email: akkuratov.evgeny@gmail.com
Sweden, Stockholm; St. Petersburg, 199034


Copyright (c) 2018 Pleiades Publishing, Ltd.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies